Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat

V. Rettori, T. Wenger, G. Snyder, S. Dalterio, S. M. McCann

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments. In conscious freely moving animals bearing implanted third ventricular (3V) and external jugular cannulae, THC or the diluent was microinjected into the 3V and blood samples were removed to determine the effect on plasma PRL and GH. Both the 0.4- and 4-μg dose injected intraventricularly resulted in a suppression of PRL and GH release as indicated by declines in plasma levels within 40-80 min which were highly significant statistically but not dose-related. The higher dose evoked a pulse of GH and/or PRL in most animals which preceded the lowering of hormonal levels. In the in vitro experiments dipersed anterior pituitary cells were incubated with 5 x 10-8 or 5 x 10-9 M THC or the diluent for 5 days. Fresh culture medium was added to the cells after 3 days and the cells cultured for an additional 2 days. After this period, the cells were incubated for an additional 2 h in culture medium with or without THC plus a near maximal dose of thyrotropin-releasing hormone and GH-releasing factor (50 and 10 ng/ml, respectively) or the diluent to evaluate the response of PRL and GH release, respectively. Neither dose of THC altered the release or storage of the two hormones during culture or affected the response to the releasing hormones which is suggestive that there is no direct effect of THC on either GH or PRL release. The results of the combined in vivo and in vitro studies indicate that the action of THC to suppress PRL and GH release is mediated within the CNS probably by suppression of aminergic activity and peptide release.

Original languageEnglish
Pages (from-to)498-503
Number of pages6
JournalNeuroendocrinology
Volume47
Issue number6
Publication statusPublished - 1988

Fingerprint

Dronabinol
Prolactin
Growth Hormone
Culture Media
Hormones
Growth Hormone-Releasing Hormone
Thyrotropin-Releasing Hormone
Cultured Cells
Neck
Peptides
In Vitro Techniques

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)

Cite this

Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. / Rettori, V.; Wenger, T.; Snyder, G.; Dalterio, S.; McCann, S. M.

In: Neuroendocrinology, Vol. 47, No. 6, 1988, p. 498-503.

Research output: Contribution to journalArticle

Rettori, V. ; Wenger, T. ; Snyder, G. ; Dalterio, S. ; McCann, S. M. / Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. In: Neuroendocrinology. 1988 ; Vol. 47, No. 6. pp. 498-503.
@article{2c95042e3995434fa95dea225d0f7af8,
title = "Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat",
abstract = "The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments. In conscious freely moving animals bearing implanted third ventricular (3V) and external jugular cannulae, THC or the diluent was microinjected into the 3V and blood samples were removed to determine the effect on plasma PRL and GH. Both the 0.4- and 4-μg dose injected intraventricularly resulted in a suppression of PRL and GH release as indicated by declines in plasma levels within 40-80 min which were highly significant statistically but not dose-related. The higher dose evoked a pulse of GH and/or PRL in most animals which preceded the lowering of hormonal levels. In the in vitro experiments dipersed anterior pituitary cells were incubated with 5 x 10-8 or 5 x 10-9 M THC or the diluent for 5 days. Fresh culture medium was added to the cells after 3 days and the cells cultured for an additional 2 days. After this period, the cells were incubated for an additional 2 h in culture medium with or without THC plus a near maximal dose of thyrotropin-releasing hormone and GH-releasing factor (50 and 10 ng/ml, respectively) or the diluent to evaluate the response of PRL and GH release, respectively. Neither dose of THC altered the release or storage of the two hormones during culture or affected the response to the releasing hormones which is suggestive that there is no direct effect of THC on either GH or PRL release. The results of the combined in vivo and in vitro studies indicate that the action of THC to suppress PRL and GH release is mediated within the CNS probably by suppression of aminergic activity and peptide release.",
author = "V. Rettori and T. Wenger and G. Snyder and S. Dalterio and McCann, {S. M.}",
year = "1988",
language = "English",
volume = "47",
pages = "498--503",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat

AU - Rettori, V.

AU - Wenger, T.

AU - Snyder, G.

AU - Dalterio, S.

AU - McCann, S. M.

PY - 1988

Y1 - 1988

N2 - The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments. In conscious freely moving animals bearing implanted third ventricular (3V) and external jugular cannulae, THC or the diluent was microinjected into the 3V and blood samples were removed to determine the effect on plasma PRL and GH. Both the 0.4- and 4-μg dose injected intraventricularly resulted in a suppression of PRL and GH release as indicated by declines in plasma levels within 40-80 min which were highly significant statistically but not dose-related. The higher dose evoked a pulse of GH and/or PRL in most animals which preceded the lowering of hormonal levels. In the in vitro experiments dipersed anterior pituitary cells were incubated with 5 x 10-8 or 5 x 10-9 M THC or the diluent for 5 days. Fresh culture medium was added to the cells after 3 days and the cells cultured for an additional 2 days. After this period, the cells were incubated for an additional 2 h in culture medium with or without THC plus a near maximal dose of thyrotropin-releasing hormone and GH-releasing factor (50 and 10 ng/ml, respectively) or the diluent to evaluate the response of PRL and GH release, respectively. Neither dose of THC altered the release or storage of the two hormones during culture or affected the response to the releasing hormones which is suggestive that there is no direct effect of THC on either GH or PRL release. The results of the combined in vivo and in vitro studies indicate that the action of THC to suppress PRL and GH release is mediated within the CNS probably by suppression of aminergic activity and peptide release.

AB - The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments. In conscious freely moving animals bearing implanted third ventricular (3V) and external jugular cannulae, THC or the diluent was microinjected into the 3V and blood samples were removed to determine the effect on plasma PRL and GH. Both the 0.4- and 4-μg dose injected intraventricularly resulted in a suppression of PRL and GH release as indicated by declines in plasma levels within 40-80 min which were highly significant statistically but not dose-related. The higher dose evoked a pulse of GH and/or PRL in most animals which preceded the lowering of hormonal levels. In the in vitro experiments dipersed anterior pituitary cells were incubated with 5 x 10-8 or 5 x 10-9 M THC or the diluent for 5 days. Fresh culture medium was added to the cells after 3 days and the cells cultured for an additional 2 days. After this period, the cells were incubated for an additional 2 h in culture medium with or without THC plus a near maximal dose of thyrotropin-releasing hormone and GH-releasing factor (50 and 10 ng/ml, respectively) or the diluent to evaluate the response of PRL and GH release, respectively. Neither dose of THC altered the release or storage of the two hormones during culture or affected the response to the releasing hormones which is suggestive that there is no direct effect of THC on either GH or PRL release. The results of the combined in vivo and in vitro studies indicate that the action of THC to suppress PRL and GH release is mediated within the CNS probably by suppression of aminergic activity and peptide release.

UR - http://www.scopus.com/inward/record.url?scp=0023934052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023934052&partnerID=8YFLogxK

M3 - Article

C2 - 2840598

AN - SCOPUS:0023934052

VL - 47

SP - 498

EP - 503

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 6

ER -